Gensight Biologics : Capital increase of € 9.2m
>Visibility out to the second part of Q3 2024 - The company has announced a capital increase of € 9.2m through issuing ABSA (Shares with warrants) at a price of € 0.395 per share, giving a discount of c.2%. The exercise price of the share subscription warrants is set at € 0.45, giving a premium of c.13%. In the case of the exercise of warrants, the dilution would be c.37%. Note that over 50% of the offering has been subscribed to by US investors such as Armistice Capi...GenSight Biologics is a clinical-stage biotechnology company based in France. Co. is engaged in discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence, or MTS, and optogenetics. Co.'s initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases. Co.'s product pipeline comprises two candidates for the treatment of sight-threatening retinal degenerative diseases, GSO1O and GSO3O.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.